Get the latest news, insights, and market updates on XERS (Xeris Biopharma Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
CHICAGO, February 17, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to d Feb 17, 2026 - $XERS
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge?
If you are wondering whether Xeris Biopharma Holdings is attractively priced or getting ahead of itself, the recent share performance gives you plenty to think about. The stock last closed at US$7.93, with returns of 7.9% over the past week, 10.6% over the past month, 7.9% year to date, 133.2% over the past year, and a very large gain over three years. Recent coverage has focused on Xeris Biopharma Holdings as a US$ small cap in the pharmaceuticals and biotech space, with attention on its... Jan 11, 2026 - $XERS
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents
Xeris Biopharma recently raised its full-year 2025 revenue outlook to approximately US$292 million, breaking past its prior US$285–US$290 million guidance range and highlighting stronger-than-expected demand for Recorlev and Gvoke. Alongside the revenue upgrade, the company bolstered its intellectual property position with new U.S. patents for Recorlev and pipeline candidate XP-8121, potentially reinforcing protection around both current and future assets. Now we’ll explore how this upgraded... Jan 10, 2026 - $XERS
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns
What Xeris Biopharma Holdings (XERS) investors are watching now Xeris Biopharma Holdings (XERS) has been on investors’ radar after a 14.3% gain over the past month and a 7.9% return year to date, prompting closer attention to its recent trading pattern. See our latest analysis for Xeris Biopharma Holdings. That recent 14.3% 30 day share price return sits alongside a 7.9% year to date share price gain, while the 1 year total shareholder return of 133.2% and very large 3 year total... Jan 10, 2026 - $XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO, January 02, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 181,550 shares of its common stock to 50 new employee(s) under Xeris’ Inducement Equity Plan. Jan 2, 2026 - $XERS
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research. In this article, we will summarize the bulls’ thesis on XERS. Xeris Biopharma Holdings, Inc.’s share was trading at $7.05 as of December 15th. XERS’s forward P/E was 64.10 according to Yahoo Finance. Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chro Dec 18, 2025 - $XERS
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed?
In early December 2025, Xeris Biopharma Holdings announced that the USPTO issued a Notice of Allowance for a patent application covering XP-8121, its investigational once-weekly, subcutaneous levothyroxine formulation using XeriSol technology, while also continuing to build broader U.S. and international intellectual property protection in the levothyroxine space. This patent milestone strengthens Xeris’ protection around XP-8121 and highlights the potential differentiation of a non-oral... Dec 6, 2025 - $XERS
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings
Xeris Biopharma Holdings has seen its narrative refreshed as analysts reaffirmed a consensus fair value estimate of $11.50 per share, while making only marginal tweaks to underlying assumptions. Backed by quarterly revenues that edged past expectations and sustained revenue growth projections of about 21.8% year over year, the updated view balances optimism over market expansion with caution around competitive and macro risks. Investors can follow these evolving analyst expectations and the... Dec 3, 2025 - $XERS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple